UA99199C2 - Pharmaceutical compositions of rosuvastatin calcium - Google Patents

Pharmaceutical compositions of rosuvastatin calcium

Info

Publication number
UA99199C2
UA99199C2 UAA201100796A UAA201100796A UA99199C2 UA 99199 C2 UA99199 C2 UA 99199C2 UA A201100796 A UAA201100796 A UA A201100796A UA A201100796 A UAA201100796 A UA A201100796A UA 99199 C2 UA99199 C2 UA 99199C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical compositions
rosuvastatin calcium
sodium carbonate
rosuvastatin
carbonate anhydrous
Prior art date
Application number
UAA201100796A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Фархад Сайяд Фарсхи
Реджеп Авджи
Сердар Апари
Original Assignee
Абди Ибрагим Иладж Санайи Ве Тиджарет Аноним Сиркети
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Абди Ибрагим Иладж Санайи Ве Тиджарет Аноним Сиркети filed Critical Абди Ибрагим Иладж Санайи Ве Тиджарет Аноним Сиркети
Priority to UAA201100796A priority Critical patent/UA99199C2/en
Publication of UA99199C2 publication Critical patent/UA99199C2/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

This invention is related to pharmaceutical compositions of rosuvastatin or pharmaceutically acceptable sails thereof especially calcium salt with sodium carbonate anhydrous which has effects on dissolution profiles in 0.1 N HCl medium provided that using of sodium carbonate anhydrous should be presence in the range of from about 0.5 % to about 2 % by weight.
UAA201100796A 2008-06-27 2008-06-27 Pharmaceutical compositions of rosuvastatin calcium UA99199C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAA201100796A UA99199C2 (en) 2008-06-27 2008-06-27 Pharmaceutical compositions of rosuvastatin calcium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAA201100796A UA99199C2 (en) 2008-06-27 2008-06-27 Pharmaceutical compositions of rosuvastatin calcium

Publications (1)

Publication Number Publication Date
UA99199C2 true UA99199C2 (en) 2012-07-25

Family

ID=50848625

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201100796A UA99199C2 (en) 2008-06-27 2008-06-27 Pharmaceutical compositions of rosuvastatin calcium

Country Status (1)

Country Link
UA (1) UA99199C2 (en)

Similar Documents

Publication Publication Date Title
TN2010000585A1 (en) Pharmaceutical compositions of rosuvastatin calcium
IN2012DN01233A (en)
UA97489C2 (en) Pharmaceutical composition containing amorphous rosuvastatin calcium
MX2020012825A (en) Multicyclic compounds and methods of use thereof.
MX351368B (en) Heteroaryl compounds and methods of use thereof.
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MX2010006241A (en) Aminotriazole derivatives as alx agonists.
UA105229C2 (en) Pharmaceutical formulation
MX2012007375A (en) 3-keto-n-propargyl-1-aminoindan.
MY151295A (en) Pyrimidyl indoline compound
EA201390163A1 (en) HETEROBICYCLIC DERIVATIVES AS HCV INHIBITORS
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
NZ601109A (en) Pharmaceutical composition comprising oligopeptides, preferably cilengitide
PL2151241T3 (en) Stable solid preparation comprising 4,5-epoxymorphinan derivative
JO3229B1 (en) Stabilization of FSH
MX2011009148A (en) Sodium salt of 5-cyclopropyl-2-{[2-(2,6- difluorophenyl)pyrimidin -5-yl]amino}benzoic acid as dhodh inhibitor.
IN2012DN02502A (en)
UA103329C2 (en) Normal;heading 1;heading 2;heading 3;SALTS OF HIV INHIBITOR COMPOUNDS
TN2012000105A1 (en) Spirolactam derivatives and uses of same
SG10201902903RA (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
MX348127B (en) Quinazolinone derivatives as hcv inhibitors.
GB201020397D0 (en) Compounds
ATE546448T1 (en) UROTENSIN II RECEPTOR ANTAGONISTS
UA99199C2 (en) Pharmaceutical compositions of rosuvastatin calcium
UA110933C2 (en) Pharmaceutical composition for treatment of essential thrombocythemia